Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAM3000 MVA Safety and Immunogenicity
NCT00133575Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2005
- Primary completion
- Apr 2008
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MVA3000 in smallpox, sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2005; status: completed.
02
Drugs
MVA3000
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00133575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00133575.